1-20 of 20
Frederick L. Locke
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

Clinical Trials & Observations
Fabiana Perna, Samir Parekh, Caroline Diorio, Melody Smith, Marion Subklewe, Rakesh Mehta, Frederick L. Locke, Nirali N. Shah
Journal: Blood Advances
Blood Adv (2024) 8 (16): 4348–4358.
https://doi.org/10.1182/bloodadvances.2024013044
Published: 2024
Journal Articles

Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7

Clinical Trials & Observations
Armin Ghobadi, Javier Munoz, Jason R. Westin, Frederick L. Locke, David B. Miklos, Aaron P. Rapoport, Miguel-Angel Perales, Patrick M. Reagan, Joseph McGuirk, Caron A. Jacobson, Marie José Kersten, Irit Avivi, Andrew Peng, Marco Schupp, Christina To, Olalekan O. Oluwole
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2982–2990.
https://doi.org/10.1182/bloodadvances.2023011532
Published: 2024
Includes: Supplemental data
Journal Articles

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Munoz, Razan Mohty, Veit L. Bücklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe
Journal: Blood Advances
Blood Adv (2024) 8 (8): 1857–1868.
https://doi.org/10.1182/bloodadvances.2023011767
Published: 2024
Includes: Supplemental data
Journal Articles

Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium

Clinical Trials & Observations
Michael D. Jain, Miriam T. Jacobs, Feng Gao, Loretta J. Nastoupil, Jay Y. Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwole, Joseph McGuirk, Abhinav Deol, Alison R. Sehgal, Andre Goy, Brian T. Hill, Charalambos Andreadis, Javier Munoz, Julio C Chavez, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David Miklos, Sattva S. Neelapu, Frederick L. Locke, Armin Ghobadi
Journal: Blood Advances
Blood Adv (2024) 8 (4): 1042–1050.
https://doi.org/10.1182/bloodadvances.2023011489
Published: 2024
Includes: Supplemental data
Journal Articles

Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy

Clinical Trials & Observations
Lauren C. Peres, Laura B. Oswald, Christen M. Dillard, Gabriel De Avila, Taiga Nishihori, Brandon J. Blue, Ciara L. Freeman, Frederick L. Locke, Melissa Alsina, Omar Castaneda Puglianini, Leyla Shune, Douglas W. Sborov, Charlotte Wagner, Danai Dima, Hamza Hashmi, James A. Davis, Mehmet H. Kocoglu, Ashraf Z. Badros, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher Ferreri, Larry D. Anderson, Jr, Aimaz Afrough, Gurbakhash Kaur, Yi Lin, Lawrence Liu, Omar Nadeem, Peter Voorhees, Jack Khouri, Joseph McGuirk, Surbhi Sidana, Doris K. Hansen, Krina Patel
Journal: Blood Advances
Blood Adv (2024) 8 (1): 251–259.
https://doi.org/10.1182/bloodadvances.2023010894
Published: 2024
Includes: Supplemental data
Journal Articles

CAR T-cell therapy has comparable efficacy with autologous transplantation in older adults with DLBCL in partial response

Othman S. Akhtar, Biwei Cao, Xuefeng Wang, Pallawi Torka, Mohammed Al-Jumayli, Frederick L. Locke, Ciara L. Freeman
Journal: Blood Advances
Blood Adv (2023) 7 (19): 5937–5940.
https://doi.org/10.1182/bloodadvances.2023010127
Published: 2023
Includes: Supplemental data
Journal Articles

Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma

Erin A. Dean, Gregory J. Kimmel, Matthew J. Frank, Ali Bukhari, Nasheed M. Hossain, Michael D. Jain, Saurabh Dahiya, David B. Miklos, Philipp M. Altrock, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4608–4618.
https://doi.org/10.1182/bloodadvances.2022009426
Published: 2023
Journal Articles

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma

Clinical Trials & Observations
Dae Hyun Lee, Abhishek Kumar, Turab Mohammed, Lauren C. Peres, Melissa Alsina, Christina Bachmeier, Brandon J. Blue, Jason Brayer, Sanjay Chandrasekhar, Ariel Grajales Cruz, Gabe De Avila, Hany Elmariah, Rawan Faramand, Ciara Freeman, Michael Jain, Sushmita Khadka, Farhad Khimani, Hien Liu, Taiga Nishihori, Laura B. Oswald, Omar A. Castaneda Puglianini, Kenneth H. Shain, Eric Smith, Rachid C. Baz, Frederick L. Locke, Guilherme H. Oliveira, Mohammed Alomar, Doris K. Hansen
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4247–4257.
https://doi.org/10.1182/bloodadvances.2023009766
Published: 2023
Journal Articles

Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma

Jennifer M. Logue, Lauren C. Peres, Hamza Hashmi, Christelle M. Colin-Leitzinger, Alexandria M. Shrewsbury, Hitomi Hosoya, Rebecca M. Gonzalez, Christina Copponex, Krista H. Kottra, Vanna Hovanky, Bita Sahaf, Sunita Patil, Aleksandr Lazaryan, Michael D. Jain, Aliyah Baluch, Olga V. Klinkova, Nelli Bejanyan, Rawan G. Faramand, Hany Elmariah, Farhad Khimani, Marco L. Davila, Asmita Mishra, Brandon J. Blue, Ariel F. Grajales-Cruz, Omar A. Castaneda Puglianini, Hien D. Liu, Taiga Nishihori, Ciara L. Freeman, Jason B. Brayer, Kenneth H. Shain, Rachid C. Baz, Frederick L. Locke, Melissa Alsina, Surbhi Sidana, Doris K. Hansen
Journal: Blood Advances
Blood Adv (2022) 6 (24): 6109–6119.
https://doi.org/10.1182/bloodadvances.2022008320
Published: 2022
Includes: Supplemental data
Journal Articles

Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL

Ariel Perez, Grace Johnson, Kedar Patel, Brian Arciola, Anthony Wood, Christina A. Bachmeier, Julio C. Chavez, Bijal D. Shah, Farhad Khimani, Taiga Nishihori, Aleksandr Lazaryan, Marco L. Davila, Rahul Mhaskar, Frederick L. Locke, Sameh Gaballa, Michael D. Jain
Journal: Blood Advances
Blood Adv (2022) 6 (13): 3970–3973.
https://doi.org/10.1182/bloodadvances.2022007006
Published: 2022
Includes: Supplemental data
Journal Articles

Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis

Mehdi Hamadani, Ajay K. Gopal, Marcelo Pasquini, Soyoung Kim, Xianmiao Qiu, Sairah Ahmed, Aleksandr Lazaryan, Vijaya Raj Bhatt, Andrew Daly, Premal Lulla, Stefan Ciurea, Jordan Gauthier, Vaibhav Agrawal, Natalie S. Grover, Lazaros Lekakis, Dipenkumar Modi, Parastoo B. Dahi, Megan M. Herr, P. Connor Johnson, Hamza Hashmi, Peiman Hematti, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2022) 6 (2): 486–494.
https://doi.org/10.1182/bloodadvances.2021005788
Published: 2022
Includes: Supplemental data
Journal Articles

A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease

Clinical Trials & Observations
Aleksandr Lazaryan, Stephanie Lee, Mukta Arora, Jongphil Kim, Brian Christopher Betts, Farhad Khimani, Taiga Nishihori, Nelli Bejanyan, Hien Liu, Mohamed A. Kharfan-Dabaja, Frederick L. Locke, Rebecca Gonzalez, Michael D. Jain, Marco L. Davila, Lia Elena Perez, Asmita Mishra, Ariel Perez Perez, Karlie Balke, Ernesto Ayala, Leonel Ochoa, Omar Castaneda Puglianini, Rawan Faramand, Melissa Alsina, Hany Elmariah, Michael L. Nieder, Hugo Fernandez, Claudio Anasetti, Joseph A. Pidala
Journal: Blood Advances
Blood Adv (2022) 6 (1): 259–269.
https://doi.org/10.1182/bloodadvances.2021005552
Published: 2022
Includes: Supplemental data
Journal Articles

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma

Clinical Trials & Observations
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, Patrick M. Reagan, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, Michael Crump, John Kuruvilla, Eric Van Den Neste, Umar Farooq, Lynn Navale, Venita DePuy, Jenny J. Kim, Christian Gisselbrecht
Journal: Blood Advances
Blood Adv (2021) 5 (20): 4149–4155.
https://doi.org/10.1182/bloodadvances.2020003848
Published: 2021
Includes: Supplemental data
Journal Articles

A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention

Clinical Trials & Observations
Lia Perez, Hugo Fernandez, Mohamed Kharfan-Dabaja, Farhad Khimani, Brian Betts, Asmita Mishra, Ernesto Ayala, Frederick L. Locke, Leonel Ochoa-Bayona, Michael Nieder, Joseph Pidala, Alex Achille, John Powers, Eva Sahakian, Ram Thapa, Xuefeng Wang, Claudio Anasetti
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2740–2750.
https://doi.org/10.1182/bloodadvances.2021004225
Published: 2021
Journal Articles

A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

Clinical Trials & Observations
Nelli Bejanyan, Joseph A. Pidala, Xuefeng Wang, Ram Thapa, Taiga Nishihori, Hany Elmariah, Aleksandr Lazaryan, Farhad Khimani, Marco L. Davila, Asmita Mishra, Rawan Faramand, Michael D. Jain, Leonel Ochoa, Lia Elena Perez, Hien Liu, Melissa Alsina, Mohamed A. Kharfan-Dabaja, Hugo Fernandez, Michael L. Nieder, Frederick L. Locke, Claudio Anasetti, Ernesto Ayala
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1154–1163.
https://doi.org/10.1182/bloodadvances.2020003779
Published: 2021
Journal Articles

Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

Clinical Trials & Observations
Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot
Journal: Blood Advances
Blood Adv (2020) 4 (19): 4898–4911.
https://doi.org/10.1182/bloodadvances.2020002394
Published: 2020
Includes: Supplemental data
Journal Articles

Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma

Clinical Trials & Observations
Hamza Hashmi, Abu-Sayeef Mirza, Alicia Darwin, Constantine Logothetis, Franco Garcia, Anuhya Kommalapati, Rahul S. Mhaskar, Christina Bachmeier, Julio C. Chavez, Bijal Shah, Javier Pinilla-Ibarz, Farhad Khimani, Aleksandr Lazaryan, Hien Liu, Marco L. Davila, Frederick L. Locke, Taiga Nishihori, Michael D. Jain
Journal: Blood Advances
Blood Adv (2020) 4 (17): 4086–4090.
https://doi.org/10.1182/bloodadvances.2020002060
Published: 2020
Includes: Supplemental data
Journal Articles

High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

Clinical Trials & Observations
Erin A. Dean, Rahul S. Mhaskar, Hong Lu, Mina S. Mousa, Gabriel S. Krivenko, Aleksandr Lazaryan, Christina A. Bachmeier, Julio C. Chavez, Taiga Nishihori, Marco L. Davila, Farhad Khimani, Hien D. Liu, Javier Pinilla-Ibarz, Bijal D. Shah, Michael D. Jain, Yoganand Balagurunathan, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3268–3276.
https://doi.org/10.1182/bloodadvances.2020001900
Published: 2020
Includes: Supplemental data
Journal Articles

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Richard T. Maziarz, Stephen J. Schuster, Vadim V. Romanov, Elisha S. Rusch, Junlong Li, James E. Signorovitch, David G. Maloney, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1440–1447.
https://doi.org/10.1182/bloodadvances.2019001305
Published: 2020
Includes: Supplemental data
Journal Articles

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James E. Signorovitch, Vadim V. Romanov, Frederick L. Locke, David G. Maloney
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1432–1439.
https://doi.org/10.1182/bloodadvances.2019001304
Published: 2020
Includes: Supplemental data